Short- and long-acting synthetic pentasaccharides

Journal of Internal Medicine

Volumn 254, Issue 4, 2003, Pages 335-342

  Koopman, Maria M W ^a   Buller H R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulant; Factor Xa inhibitor; Pentasaccharide

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PIROXICAM; PROTHROMBIN A; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; UNCLASSIFIED DRUG; WARFARIN;

ACUTE HEART INFARCTION; BLEEDING; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DRUG RELEASE; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; LUNG EMBOLISM; META ANALYSIS; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOEMBOLISM;

ACUTE DISEASE; ANTICOAGULANTS; BLOOD COAGULATION; CORONARY DISEASE; FACTOR XA; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; OLIGOSACCHARIDES; POLYSACCHARIDES; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOSIS;

EID: 0141527584     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01226.x     Document Type: Conference Paper

References (31)

1. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
2. Koopman MM, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 682-7.
3. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
4. Hirsh J, Dalen J, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
5. Petitou M, van Boeckel CA. Chemical synthesis of heparin fragments and analogues. Fortschr Chem Org Naturst 1992; 60: 143-210.
6. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-38.
7. Amiral J, Lormeau JC, Marfaing-Koka A et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 114-7.
8. Boneu B, Necciari J, Cariou R et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
9. Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41: 1-9.
10. Herbert JM, Petitou M, Lormeau JC et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15: 1-26.
11. Donat F, Duret A, Santoni A et al. Pharmacokinetics of Org31540/Sr90107A in young and elderly healthy subjects: a highly favourable pharmacokinetic profile. Thomb Haemost 2001; Suppl.: p3094 (CD-ROM).
12. Faaij RA, Burggraaf J, Schoemaker RC, de Greef R, Cohen AF. The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin. Clin Pharmacokinet 2002; 41: 27-29.
13. Ollier C, Faaij RA, Santoni A et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 31-37.
14. Lieu C, Shi J, Donat F et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002; 41: 19-26.
15. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S-75S.
16. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-25.
17. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
18. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-6.
19. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
20. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
21. Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-6.
22. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
23. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Influence of the duration of fondaparinux prophyldxis in preventing venous thromboembolism following hip fracture surgery. Blood 2002; 100: 304 (Abstract).
24. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
25. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000; 102: 2726-31.
26. Fondaparinux (arixtra) in comparison to (low-molecular weight) heparin for the initial treatment of symptomatic deep-venous thrombosis or pulmonary embolism - the Matisse clinical outcome studies. Blood 2002; 100: 302 (Abstract).
27. Coussement PK, Bassand JP, Convens C et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001; 22: 1716-24.
28. Scientific Session of the American Heart Association. Pentasaccharides in patients with unstable angina - The Pentua study. Presented at the 74th Scientific Session of the American Heart Association. Scientific Session of the American Heart Association.
29. Bijsterveld NR, Moons AH, Boekholdt SM et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-4.
30. Herbert JM, Herault JP, Bernat A et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.
31. A novel long acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. The Persist Investigators. Blood 2002; 100: 301 (abstract).